GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
4.380 USD   -7.79%
07:01aGritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on GRITSTONE BIO, INC.
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
03/14HC Wainwright Adjusts Gritstone Bio's Price Target to $15 From $24, Maintains Buy Ratin..
MT
2021GRITSTONE ONCOLOGY : BTIG Research Adjusts Gritstone Oncology PT to $35 From $17, Maintain..
MT
2021GRITSTONE ONCOLOGY : HC Wainwright Adjusts Gritstone Oncology's Price Target to $24 from $..
MT
2021GRITSTONE ONCOLOGY : Baird Downgrades Gritstone Oncology to Underperform From Outperform; ..
MT
Upcoming event on GRITSTONE BIO, INC.